Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of α-Synuclein and Cholesterol by Threlfell, Sarah et al.
Striatal Dopamine Transporter Function Is Facilitated by
Converging Biology of a-Synuclein and Cholesterol
Downloaded from: https://research.chalmers.se, 2022-01-01 18:21 UTC
Citation for the original published paper (version of record):
Threlfell, S., Mohammadi, A., Ryan, B. et al (2021)
Striatal Dopamine Transporter Function Is Facilitated by Converging Biology of a-Synuclein and
Cholesterol
Frontiers in Cellular Neuroscience, 15
http://dx.doi.org/10.3389/fncel.2021.658244
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
ORIGINAL RESEARCH




University at Albany, United States
Reviewed by:
Aurelio Galli,
University of Alabama at Birmingham,
United States
Sara Raulerson Jones,








†These authors share last authorship
Specialty section:
This article was submitted to
Cellular Neurophysiology,
a section of the journal
Frontiers in Cellular Neuroscience
Received: 25 January 2021
Accepted: 22 March 2021
Published: 15 April 2021
Citation:
Threlfell S, Mohammadi AS, Ryan BJ,
Connor-Robson N, Platt NJ,
Anand R, Serres F, Sharp T,
Bengoa-Vergniory N,
Wade-Martins R, Ewing A, Cragg SJ
and Brimblecombe KR (2021) Striatal
Dopamine Transporter Function Is
Facilitated by Converging Biology of
α-Synuclein and Cholesterol.
Front. Cell. Neurosci. 15:658244.
doi: 10.3389/fncel.2021.658244
Striatal Dopamine Transporter
Function Is Facilitated by Converging
Biology of α-Synuclein and
Cholesterol
Sarah Threlfell1,2, Amir Saeid Mohammadi3, Brent J. Ryan1,2, Natalie Connor-Robson1,2,
Nicola J. Platt1, Rishi Anand1, Florence Serres4, Trevor Sharp4,
Nora Bengoa-Vergniory1,2, Richard Wade-Martins1,2, Andrew Ewing5,
Stephanie J. Cragg1,2*† and Katherine R. Brimblecombe1,2*†
1Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom, 2Oxford Parkinson’s
Disease Centre, Medical Sciences Division, University of Oxford, Oxford, United Kingdom, 3Department of Chemistry and
Chemical Engineering, Chalmers University of Technology, Gothenburg, Sweden, 4University Department of Pharmacology,
University of Oxford, Oxford, United Kingdom, 5Department of Chemistry and Molecular Biology, University of Gothenburg,
Gothenburg, Sweden
Striatal dopamine transporters (DAT) powerfully regulate dopamine signaling, and can
contribute risk to degeneration in Parkinson’s disease (PD). DATs can interact with
the neuronal protein α-synuclein, which is associated with the etiology and molecular
pathology of idiopathic and familial PD. Here, we tested whether DAT function in
governing dopamine (DA) uptake and release is modified in a human-α-synuclein-
overexpressing (SNCA-OVX) transgenic mouse model of early PD. Using fast-scan cyclic
voltammetry (FCV) in ex vivo acute striatal slices to detect DA release, and biochemical
assays, we show that several aspects of DAT function are promoted in SNCA-OVX
mice. Compared to background control α-synuclein-null mice (Snca-null), the SNCA-
OVX mice have elevated DA uptake rates, and more pronounced effects of DAT inhibitors
on evoked extracellular DA concentrations ([DA]o) and on short-term plasticity (STP)
in DA release, indicating DATs play a greater role in limiting DA release and in driving
STP. We found that DAT membrane levels and radioligand binding sites correlated with
α-synuclein level. Furthermore, DAT function in Snca-null and SNCA-OVX mice could
also be promoted by applying cholesterol, and using Tof-SIMS we found genotype-
differences in striatal lipids, with lower striatal cholesterol in SNCA-OVX mice. An inhibitor
of cholesterol efflux transporter ABCA1 or a cholesterol chelator in SNCA-OVX mice
reduced the effects of DAT-inhibitors on evoked [DA]o. Together these data indicate
that human α-synuclein in a mouse model of PD promotes striatal DAT function, in
a manner supported by extracellular cholesterol, suggesting converging biology of α-
synuclein and cholesterol that regulates DAT function and could impact DA function and
PD pathophysiology.
Keywords: dopamine transporter (DAT), alpha-synuclein (SNCA), cholesteroI, striatum, Parkinson’s disease, early
stage parkinsonism, dopamine uptake, galactoceramide
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INTRODUCTION
Striatal dopamine (DA) release is regulated by mechanisms
that drive activity in midbrain DA neurons in conjunction
with mechanisms in striatum that act on and within DA
axons (Sulzer et al., 2016). DA uptake transporters (DATs)
on DA axons clear striatal DA from the extracellular space
to spatially and temporally limit DA signaling (Cragg and
Rice, 2004). In addition, it has become evident that striatal
DATs also regulate the underlying process of DA release.
Inhibition of DATs with pharmacological inhibitors not only
limits the uptake but also promotes the amount of DA released
(John and Jones, 2007) through a synapsin-dependent pathway
(Venton et al., 2006; Kile et al., 2010) suggesting that the
DAT limits vesicular mobilization for release. In addition,
DATs regulate the short-term dynamic plasticity of DA release,
promoting subsequent release at short inter-pulse intervals (IPIs)
corresponding to high frequency firing, and limiting subsequent
release at longer IPIs corresponding to low frequency firing
(Condon et al., 2019).
Besides their role in regulating DA release and uptake, DATs
are implicated in the etiology of Parkinson’s disease (PD). DATs
offer a route of entry to DA neurons-of environmental toxins
e.g., MPTP, pesticides (Lehmensiek et al., 2006; Ritz et al.,
2009), and higher DAT expression and DAT: VMAT ratios
promote oxidative stress via dopamine oxidation and consequent
dopamine neuron loss (Miller et al., 1999; Masoud et al., 2015).
Variations in the DAT/SLC6A3 gene that are associated with
PD susceptibility increase the expression of striatal DAT (van
de Giessen et al., 2009; Richter et al., 2017). Furthermore,
the DAT is electrogenic, offering depolarizing currents, which
can be uncoupled from translocation of DA (Sonders et al.,
1997), and so contribute to a metabolic burden, requiring
ATP to re-establish ion gradients across the axonal membrane
(Pissadaki and Bolam, 2013).
DAT function is regulated by post-translational modifications
and lipid- and protein-binding partners (Vaughan and Foster,
2013), including α-synuclein (Lee et al., 2001) and cholesterol
(Jones et al., 2012). DATs co-localize with α-synuclein in human
post-mortem tissue (Bellucci et al., 2011) andmany aspects of the
DAT are reported to be affected by α-synuclein, including surface
expression, internalization, DA translocation, and sensitivity to
ligands. However, there is a lack of consensus about the impact
of α-synuclein on DAT function, with conflicting evidence
showing that DAT function can be enhanced (Lee et al., 2001;
Chadchankar et al., 2011), decreased (Wersinger and Sidhu,
2003; Swant et al., 2011; Lundblad et al., 2012), or remains
unaffected (Abeliovich et al., 2000). This lack of consensus
might reflect the differing experimental preparations, assays and
aspect of DAT function explored, and also might arise from the
different structural forms (monomeric, oligomeric or fibrillary,
soluble or aggregated) of α-synuclein that might be differently
present (Alegre-Abarrategui et al., 2019) and have different
pathophysiological outcomes. Determining the structural form
and binding partners of α-synuclein is non-trivial and has been
reviewed elsewhere (Alegre-Abarrategui et al., 2019; Alza et al.,
2019). In addition, α-synuclein is in an equilibrium between
cytosolic and membrane-bound states and cholesterol has been
shown to affect the position of this equilibrium (Man et al., 2020).
Cholesterol is a key component of highly curved membranes
including synaptic vesicles, which α-synuclein can associate with
(Galvagnion, 2017).
Here, we assessed whether DAT function is modified in the
SNCA-OVX mouse model of early PD relative to Snca-null
background control mice. SNCA-OVXmice are devoid of mouse
α-synuclein but overexpress human wild-type α-synuclein at
disease-relevant levels modeling SNCA locus multiplication seen
in PD (Singleton et al., 2003). They show early deficits in DA
release prior to DA cell loss, behavioral deficits in old age (Janezic
et al., 2013), and progressive α-synuclein oligomerization with
age compared to Snca-null mice (Bengoa-Vergniory et al., 2020)
but in the absence of aggregation (Janezic et al., 2013). The
control Snca-null mice do not differ from wild-type mice in DA
release levels using our stimulation protocols (Senior et al., 2008).
We assessed whether the SNCA-OVX PDmodel has altered DAT
function in DA release or uptake by the DAT, and explored a
potential point of convergence with cholesterol biology, using
fast-scan cyclic voltammetry, molecular biology and ToF-SIMS.
MATERIALS AND METHODS
Mice
All procedures were conducted in accordance with the United
Kingdom Animals (Scientific Procedures) Act of 1986 and
approved by the local ethical review panel at the Department
of Physiology, Anatomy and Genetics, University of Oxford.
SNCA-OVX mice (B6.Cg-Tg(SNCA)OVX37Rwm Sncatm1Rosl/J;
Jackson Laboratories stock no. 023837) are BAC-transgenic mice
that overexpress human α-synuclein from the SNCA genomic
locus at Parkinson’s disease-relevant levels, and are back-crossed
onto a mouse α-synuclein-null (Snca-null) background. SNCA-
OVX and their litter-mate Snca-null background control mice
were produced as described previously (Janezic et al., 2013).
Mice were age-(3–20 months) and sex-matched throughout.
Data from male and female mice were combined given there
were no apparent differences between the effects of cocaine on
DA release between the sexes in both genotypes (Supplementary
Figure 5). DAT-Cremice (DATIRESCREJax stock number 006660)
were homozygote 4-month old males, generated by crossing
heterozygous mice.
Proximity Ligation Assay (PLA)
DAT:α-synuclein PLA experiments were carried out using
Duolinkr in situ kits supplied by Sigma Aldrich according to
the manufacturer’s instructions, and an α-synuclein antibody
(syn4D6 ab1903, Abcam), and a DAT antibody (ab5990, Abcam).
Briefly, the conjugates were prepared using the DuoLinkr
Probemaker kit by incubating 20 µl of each antibody (1 mg/ml)
with the Probemaker activated oligonucleotide (Plus and Minus
respectively) and conjugation buffer and leaving it overnight at
room temperature. Conjugates were incubated with Probemaker
stop solution for 30 min at room temperature and then
suspended in Probemaker storage buffer. Paraffin-embedded
tissue was prepared for fluorescent PLAr by dewaxing in
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xylene and histoclear, rehydrating via graded alcohols, blocking
endogenous peroxidases with 10% H2O2 for 15 min at room
temperature, followed by antigen retrieval using microwave heat
(10 min total) and citrate buffer pH 6 (ab93678, Abcam). All
samples were incubated in Duolinkr block solution for 1 h at
37◦C, followed by conjugates diluted in Duolinkr PLA diluent
(both DAT and α-synuclein 1:100) overnight at 4◦C. After
washing in TBS + 0.05% Tween 20, samples were incubated
with Duolinkr ligation solutions and ligase for 1 h at 37◦C,
before washing and incubation with Duolinkr amplification
reagents and polymerase for 2.5 h at 37◦C. Samples were then
washed with Duolinkr wash buffer B andmounted/coverslipped
with Fluorsave (Calbiochem). Images were blindly acquired at
three distinct sites in dorso-medial, dorso-mid and dorso-lateral
striatum from a single 5 µm coronal section per mouse, and
puncta were automatically counted with ImageJ. Three mice per
genotype were assessed.
DAT Immunofluorescence
Paraffin-embedded mouse brains from SNCA-OVX and Snca-
null mice were sectioned to 5 µm. Paraffin-embedded tissue was
prepared for immunofluorescence by dewaxing in xylene and
histoclear, rehydrating via graded alcohols, blocking endogenous
peroxidases with 10% H2O2 for 15 min at room temperature,
followed by antigen retrieval using microwave heat (10 min
total) and citrate buffer pH 6 (ab93678, Abcam). The tissue
was blocked for 1 h at room temp (TBS containing 1 M
glycine, 10% normal goat serum and 0.1% Triton) prior to
incubating in DAT primary antibody (rat anti-DAT; ab5990,
Abcam) overnight at 4◦C. Following washes in TBS + 0.1%
Triton, the tissue was incubated in secondary antibody (Alexa
Fluor 488 Goat anti-rat, Life Technologies) for 1 h at room
temperature. Sections were then washed and coverslipped with
FluorsaveTM (Calbiochem). Images were taken blindly in dorso-
mid, dorso-medial and dorso-lateral striatum from two coronal
sections, three mice per genotype were quantified automatically
with ImageJ.
3H-Cocaine Autoradiography
Mice (three per group; 3–4 months old) were sacrificed
by cervical dislocation and the brains immediately collected
and snap-frozen in isopentane. Coronal sections (20 µm)
were sectioned on a cryostat at the level of the striatum
(plates 18–24; Franklin and Paxinos, 2004), thaw-mounted
onto gelatinized slides, and stored at −80◦C until use. Slides
were defrosted and air-dried at room temperature before being
pre-incubated for 10 min in an ice-cold PBS buffer (150 mM
NaCl, 10 mM NaHPO4, pH7.4). Slides were then incubated
at 4◦C for 30 min in a PBS buffer containing [3H]-cocaine
(1 µM; Perkin Elmer). Non-specific binding was determined
in presence of GBR 12935 (1 µM). After incubation, slides
were washed twice in ice-cold PBS and left to dry. Slides
were then put in contact with film (Kodak MR) for 6 weeks.
Densitometric analysis of the autoradiograms was performed
against 3H-microscales (Amersham, UK) using a computerized
imaging system (MCID Core, version 7.0, Interfocus Imaging
Limited, UK) and subsequently normalized to Snca-null.
Western Blots
Protein extraction and Western analysis was performed as
previously described (Janezic et al., 2013). Striatal tissue was
homogenized in PBS (pH 7.4) containing 1% Igepal CA-
630, 0.1% SDS, 0.5% sodium deoxycholate, and protease
inhibitor mixture using a Tissue Tearor (Biospec Products,
Inc.). Protein content was quantified using a BCA assay
kit (Sigma) and proteins were analyzed by Western blotting
under reducing, non-denaturing conditions. Primary antibodies
used were: mouse anti-alpha synuclein 1:500 (Abcam ab1903)
and rat anti-DAT 1:1,000 (Millipore; mab369) and anti-beta
actin (HRP-conjugated) antibody (Abcam ab49900) at 1:50,000.
Bands were visualized using horseradish peroxidase-conjugated
goat anti-mouse or goat anti-rat IgG (Bio-Rad) and the
chemiluminescent ECL+ kit (GE Healthcare) or immobilon ECL
(Millipore). Bands were quantified using ImageJ software.
Fast-Scan Cyclic Voltammetry
Sex- and age-matched adult mice (3–20 months) were killed
via cervical dislocation and the brains were removed quickly
on ice and transferred into ice-cold oxygenated HEPES-based
buffer) in mM: 120 NaCl, 20 NaHCO3, 6.7 HEPES acid, 5KCL,
3.3 HEPES salt, 2 CaCl2, 2 MgSO4, 1.2 K2PO4 and 10 glucose)
saturated with 95%O2/5% CO2. Three-hundred micrometer
coronal slices containing striatum (+1.1 to +1.4 mm anterior
of Bregma; Franklin and Paxinos, 2004) were taken and left
to recover at room temperature in HEPES-based bugger for
at least 1 h prior to transferring to recording chamber and
to aCSF (in mM: 124 NaCl, 62 NaHCo3, 3.8 KCl, 2.4 CaCl2,
1.3 MgSO4, 1.3 KH2PO4 and 10 glucose) saturated with 95%
O2/5% CO2 for recording. Slices were warmed to 32◦C and
carbon fiber microelectrode (CFM) inserted into non recording
site for charging for 30 min prior to recording.
Carbon-fiber microelectrodes were manufactured in-house
using borosilicate glass (GC200F-10, Harvard Apparatus) and
epoxy-free carbon fiber (7 µm diameter; Goodfellow). Voltage
waveform (−0.7 V to +1.3 V) was scanned at 8 Hz at 800 V/s
across the recording CFM and switched out of circuit between
scans using a Millar Voltammeter as described previously
(Threlfell et al., 2010, 2012).
Single recording sites in either dorsomedial or dorsolateral
caudate putamen (CPu) were selected and multiple stimulation
paradigms were delivered in a pseudo-random order with
2.5 min intervals between stimulations. Following a period
of recording to establish a stable baseline in control or drug
conditions, at least three repeats of each stimuli weremade within
a given condition—e.g., aCSF control or drug. These repeats
were then averaged within an experiment and normalized and
averaged across different animals to obtain a mean effect of a
drug. At least three animals per experiment were used (N).
To assess dopamine reuptake kinetics in SNCA-OVX and
Snca-null we used two different approaches.We used exponential
decay curve fits and Michaelis-Menten models to fit the falling
phases of evoked DA transients using GraphPad Prism 6.0.
Exponential curve fits were applied to individual transients
concentration-matched between genotypes, and fitted over 1 s to
extract rate constants, k. Conditions designed tomaximize [DA]o
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 April 2021 | Volume 15 | Article 658244
Threlfell et al. DAT Regulation by α-Synuclein, Cholesterol
and thereby approach levels that might approachVmax were train
stimuli of 20 pulses at 100 Hz delivered in the presence of Kv+-
channel blocker 4-AP (100 µM), nicotinic acetylcholine receptor
blocker DHβE (1 µM) and D2 receptor antagonist L-741,626
(1 µM).
In experiments applying cholesterol, slices were
pre-incubated for 1 h in water soluble (ws)-cholesterol
(50 µg/ml) or vehicle (methyl-β-cyclodextrin; 1 mM) prior
to transferring to the recording chamber. For probucol treated
experiments, slices were incubated in probucol (5 µM) or
DMSO vehicle control for 30 min then transferred to recording
chamber with probucol (5 µM) present in the superfusate
throughout recording. For nystatin treated experiments slices
were incubated in nystatin (25 or 100 µg/ml) or vehicle control
(DMSO) for 30 min and then transferred to recording chamber
due to potential interactions with the CFM.
Drugs
Dihydro-β-erythroidine (DHβE), nomifensine maleate salt, GBR
12935, L-741,626, 4-Aminopyridine and nystatin were purchased
from Tocris Bioscience. Cocaine, methyl-β-cyclodextrin and
ws-cholesterol were purchased from Sigma–Aldrich. Nystatin
was purchased from Abcam. Drugs were dissolved in distilled
water, DMSO (GBR 12935, L-741,626, probucol and nystatin)
or 0.1 M HCl (nomifensine) to make stock aliquots at
1,000–10,000× final concentrations and stored at −20◦C until
required. Stock aliquots were diluted with oxygenated aCSF to
the final concentration immediately before use. Nystatin and
methyl-β-cyclodextrin and ws-cholesterol were prepared fresh
prior to each use.
Secondary Ion Mass Spectrometry
(Tof-SIMS)
Frozen brain samples were sectioned at−20◦C to 6µm thickness
and the slices containing both CPu and NAc were mounted
on ITO glass slides. The brain tissue samples were stored in
capped containers at −80◦C until SIMS analysis. The sections
were dehydrated in a vacuum desiccator for 30 min. ToF-SIMS
analysis was performed using a J105 3D mass spectrometry
imaging instrument (Ionoptika, Limited, U.K.). The instrument
was equipped with a continuous 40 keV primary gas cluster
ion beam (GCIB) to analyze the samples and clusters of CO2
gas (AGA, Sweden) with a nominal size of 6,000 [(CO2)6,000+]
were utilized as the primary analysis ion beam. The ion dose
density was kept below the static limit (1× 1013 ions/cm2), in
order to minimize surface damage. Spectra were obtained over
a mass range of 100–1,000 Da and the mass resolution was
approximately 5,000–8,000 in the range of intact phospholipids.
In order to perform statistical analysis and comparison between
SNCA-OVX and Snca-null mice, data were collected from three
animals per genotype and from four slices per mouse. Data were
normalized to the total ion counts obtained in the measured
mass range.
Statistical Analysis
All data are expressed as means± SEM (unless otherwise stated)
and the sample size, n = technical repeats and N = number
of animals. The number of animals in each data set was ≥3.
Parametric tests were used for data sets with equal variances
and passed normality tests (D’Agostino and Pearson normality
test). Subsequently, comparisons for differences in means were
assessed using unpaired t-tests, or Mann–Whitney tests or one-
or two-way ANOVAs with post hoc Sidak’s multiple comparison
tests using GraphPad Prism 6.0. Michaelis–Menten fits used
GraphPad Prism.
RESULTS
DAT Function Is Potentiated by
α-Synuclein
In mice expressing human α-synuclein on a mouse α-
synuclein-null background (SNCA-OVX; Janezic et al., 2013), we
used fast-scan cyclic voltammetry to test whether α-synuclein
expression affected properties of DA release in ex vivo slices
that are regulated by DAT. Initially, we ensured that we could
replicate previously published finding that striatal DA release
is impaired in SNCA-OVX compared to Snca-null mice by
3 months—(Janezic et al., 2013). In control conditions, [DA]o
release evoked by a single local electrical pulse in the dorsal
striatum was 34% lower in SNCA-OVX compared to Snca-null
(Figures 1A,B, 1.69± 0.11 µM vs. 2.57± 0.20 µM), in line with
previous findings. Local electrical stimuli evoke DA release by
direct depolarization of DA axons and indirectly by activating
nAChRs on DA axons following evoked ACh release from
cholinergic interneurons (Cachope et al., 2012; Threlfell et al.,
2012; Wang et al., 2014). Therefore, we also tested whether the
DA deficit in SNCA-OVX mice is present when the ACh-driven
portion of DA release is prevented. In the presence of nAChR
antagonism (DHβE 1 µM), levels of [DA]o evoked by a single
electrical pulse were lower than in drug-free media as previously
published (Rice and Cragg, 2004), and, remained 34% lower in
SNCA-OVX vs. Snca-null mice (Figures 1A,B, 0.37 ± 0.03 µM
vs. 0.69± 0.05 µM).
Next, we explored DA uptake kinetics using several
approaches. We first extracted decay constants, k, from single-
phase exponential decay curves fitted to concentration-matched
[DA]o transients evoked by either single pulse or stimulation
protocols that drive elevated [DA]o (20p 100 Hz in DHβE,
4AP, L741–626). k was significantly greater in SNCA-OVX
than Snca-null mice indicating faster uptake kinetics, for both
stimulus protocols when analyzed either separately (Figure 1C)
or in combination (Figures 1D,E). Second, we constructed a
Michaelis–Menten-like plot, of the maximum decay rate (V)
found on falling transients plotted vs. [DA]o and found that
both Vmax and Km of the best-fit curves were greater in SNCA-
OVX than Snca-null mice (Figure 1F, Vmax: 11.8 vs. 7.2 µM/s;
Km: 4.0 vs. 1.8 µM). We then tested whether the altered DAT
function in SNCA-OVX was reflected by differential effects of
DAT inhibition on [DA]o. Indeed, inhibition of DAT with
either cocaine (5 µM), GBR 12935 (10 µM) or nomifensine
(10 µM) resulted in a greater enhancement of evoked [DA]o
in SNCA-OVX vs. Snca-null mice (Figures 1G,H). We explored
whether the changes to DAT function might be an adaptation
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to, or conversely arise independently from, a deficit in evoked
DA release levels in SNCA-OVX mice (Janezic et al., 2013) as
chronic DA levels can impact DAT function (Calipari et al.,
2013; Siciliano et al., 2018; Brodnik et al., 2020). In particular
we tested whether the effect of cocaine was greater in SNCA-
OVX vs. Snca-null mice in the NAc where, in contrast to dorsal
striatum, there is no deficit in evoked [DA]o (Janezic et al., 2013),
and found that the effect of cocaine on 1p-evoked [DA]o was
similarly enhanced in NAc of SNCA-OVXmice (Supplementary
Figure 1) indicating that altered DAT function in SNCA-OVX
mice occurs is not due to a DA release deficit.
In addition, we have recently shown that the DAT is
a powerful regulator of short-term plasticity in DA release,
whereby the DAT promotes a strong inverse relationship
between [DA]o released at a subsequently paired pulse (paired-
pulse ratio) and interpulse interval (IPI; Condon et al., 2019). We
tested whether elevated DAT function in SNCA-OVX resulted
in this relationship being promoted. Indeed, we found a slightly
steeper inverse relationship between paired-pulse ratio and IPI
in SNCA-OVX vs. Snca-null (Figure 1I; in the presence of
nicotinic receptor antagonism to prevent the confounding effects
of ACh (Rice and Cragg, 2004). In turn, for short bursts of
4 pulses, there was a steeper relationship between frequency and
evoked [DA]o in SNCA-OVX vs. Snca-null (Figure 1J). These
differences between genotypes were ameliorated by cocaine
(Figures 1I,J), which weakened the relationship of [DA]o to IPI
and frequency in both genotypes, as seen previously in wild-type
mice (Condon et al., 2019).
DAT Availability Is Increased by
α-Synuclein
To understand the enhanced DAT function in SNCA-OVX
striatum we explored how DATs and α-synuclein interact. Using
a proximal ligation assay (PLA) we identified that DATs form a
close spatial arrangement with α-synuclein (<40 nm) in SNCA-
OVX mice (Figures 2A,B), supporting the hypothesis that α-
synuclein and DAT associate. We tested whether α-synuclein
expression increased DAT levels using western blot. However,
under reducing conditions we found no difference in total
striatal DAT levels between wild-type mice (Snca-wt), Snca-
null, or SNCA-OVX mice (Figures 2C,D). To validate these
data, and in particular, as a positive control for the ability
of western blotting to detect differences in DAT levels, we
confirmed that we could detect the lower DAT levels seen
in DAT-Cre+/+ mice compared to controls (Bäckman et al.,
2006). In parallel with these low levels of DAT we confirmed
in DAT-Cre mice that uptake rates for released DA were
correspondingly low and that there were only modest effects
of cocaine on peak [DA]o and paired-pulse ratios detected
with FCV (Supplementary Figures S2A,B). Consequently, the
elevated DAT function in SNCA-OVX mice seems not due to
different level of total DAT, suggesting that DAT function might
be affected at the level of the cell surface. We tested whether α-
synuclein could be revealed to modify the levels of DAT levels
under more native conditions using two different assays. We
immunolabeled DAT in striatum and found greater levels of
DAT-immunoreactivity in SNCA-OVX vs. Snca-null striatum
(Figures 2E,F). We also used autoradiography with [3H]-cocaine
to determine the relative density of striatal DAT binding sites,
and found levels to be about 2.5 times higher in SNCA-OVX
mice compared to Snca-null mice, with intermediate levels seen
in wild-type mice Snca-wt; Figures 2G,H). The relative level of
transporter binding, SNCA-OVX > Snca-wt > Snca-null tallies
with the order of relative effect size of cocaine on increasing
peak 1p-evoked [DA]o seen with cocaine in these genotypes in
our hands, which is respectively 2.5-fold in SNCA-OVX> 2-fold
in wild-types (Condon et al., 2019) > and 1.8-fold in Snca-null
(Figure 1). These differences between SNCA-OVX and Snca-
wt mice also correlate with the relative expression levels of
pan-species α-synuclein, whereby SNCA-OVX expresses human
α-synuclein at 2-fold the level of mouse α-synuclein seen in Snca-
wt mice (Figure 2I), as previously published (Janezic et al., 2013).
Together these data illustrate that DAT and α-synuclein form
a close spatial interaction and that α-synuclein promotes DAT
availability to bind its ligand.
Cholesterol Promotes DAT Function
There is a complex reciprocal relationship between α-synuclein
and cholesterol, whereby cholesterol can influence α-synuclein
levels and structural forms, and cholesterol levels have been
reported to depend on α-synuclein expression (Barceló-Coblijn
et al., 2006; Don et al., 2014; Ronzitti et al., 2014; Mazzulli
et al., 2016; Galvagnion, 2017; Hsiao et al., 2017; Alecu and
Bennett, 2019) and furthermore, somewhat analogously to our
findings with α-synuclein and DAT function, cholesterol has
been shown to promote ligand binding to DAT (Hong and
Amara, 2010; Morissette et al., 2018) and enhance DA transport
(Jones et al., 2012; Morissette et al., 2018). We therefore explored
whether there is converging biology between α-synuclein and
cholesterol and DAT function in SNCA-OVX mice. Firstly, we
tested whether applied cholesterol could phenocopy the effect of
α-synuclein level on DAT function. Application of water-soluble
cholesterol (50 µg/ml) decreased [DA]o evoked by a single pulse
in Snca-null mice (Figure 3A), and increased the rate constant k
for exponential curve-fits to the falling phase of concentration-
matched transients, indicating that applied cholesterol increases
DA clearance (Figure 3B, k, 2.54 vs. 3.14 s−1, P < 0.0001).
Furthermore, applied cholesterol enhanced the effect of cocaine
on peak [DA]o evoked by a single pulse in Snca-null mice
(Figure 3C) and also in SNCA-OVX mice (Figure 3D). There
was no difference in the effect of cocaine between vehicle
and drug free conditions (Supplementary Figure 3). To
explore whether cholesterol levels might be modified in SNCA-
OVX mice, we measured cholesterol content of striatal tissue
membranes using ToF-SIMS. We found that levels of cholesterol
in SNCA-OVX mice were significantly lower than those in
Snca-null mice, whereas levels of galactosylceremide (32:1) were
higher (Figures 3E,F), which was not due to any difference
in glucocerebrosidase (GBA) activity, unlike previous findings
(Galvagnion, 2017; Supplementary Figure 4).
The finding that cholesterol content is lower in SNCA-
OVX mice might at first seem counterintuitive, given that DAT
function is enhanced in SNCA-OVX mice and by application
of ws-cholesterol. However, these findings would be consistent
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FIGURE 1 | Dopamine transporters (DAT) function is potentiated by α-synuclein. (A) Mean [DA]o ± SEM (shaded) evoked by single pulses (arrow) vs. time in
caudate putamen (CPu) of Snca-null (dashed line) and SNCA-OVX (solid line) mice in drug-free conditions (left) or DHβE (right). (B) Summary of peak evoked [DA]o.
***P < 0.001, two-way ANOVA main effect of genotype: F(1,90)= 14.54, P = 0.0003; drug x genotype interaction: F(1,90)= 3.19, P = 0.078. (C,D) One-phase
exponential decay curve fits for falling phases of the mean of concentration-matched [DA]o transients evoked by a single pulse (C) or 20p 20 Hz in the presence of
DHBE (1 µM), 4-aminopyridine (100 µM), L-741,626 (1 µM) (D), for Snca-null and SNCA-OVX mice. Insets, transients offset to allow for concentration-matching
(arrow). Comparison of k, Snca-null vs. SNCA-OVX: 1p, 2.39 vs. 2.92, F(1,825) = 64.5, P < 0.0001; 20p, 1.29 vs. 1.73, F(1,842)= 53.01, P < 0.0001. (E) Summary of k
(s−1) calculated for all transients, 2.34 vs. 3.13, t(123) = 3.35, **P = 0.0011. (F) Maximum decay rates seen for each transient vs. [DA]o at that rate for Snca-null
(unfilled) and SNCA-OVX (filled). Unconstrained Michelis–Menten curve-fits for null (dashed) and SNCA-OVX (solid). Vmax and Km are indicated by horizontal and
vertical lines. Vmax = 7.20 vs. 11.84 µM/s, Km = 1.82 vs. 3.97 µM, comparison of fits: F(2,181) = 15.75, P < 0.001, R2 = 0.52 and 0.80. (G) Mean [DA]o (µM) ± SEM
vs. time evoked by single pulses (arrow) in CPu, before cocaine (control, black line) and in the presence of cocaine (blue, 5 µM). (H) Summary of effects of DAT
inhibitors cocaine, GBR 12935 and nomifensine on 1p-evoked [DA]o in Snca-null and SNCA-OVX, two-way ANOVA: effect of drug, F(2,28)= 18.63, P < 0.0001; effect
of genotype, F(1,28) = 18.67, P = 0.0002; genotype x cocaine interaction, F(2,28) = 0.91, P = 0.41. (I) Paired-pulse ratios (PPR) for [DA]o vs. inter-pulse interval (IPI) in
control conditions (DHβE; black), and with cocaine (blue) in Snca-null (unfilled) and SNCA-OVX (filled). Two-way ANOVA: condition x IPI interaction, F(12,100) = 137.9,
P < 0.0001, Sidak’s post-test ***P < 0.001. (J) Peak [DA]o (normalized to condition 1p) ± SEM vs. frequency for 4p trains (5–100 Hz) in control (in the presence of
DHβE; black) and cocaine (blue) in Snca-null (unfilled) and SNCA-OVX (filled). Two-way ANOVA: condition x frequency interaction, F(12,40) = 19.56, P < 0.0001,
Sidak’s posttest: ***P < 0.001. Insets, normalized effect of cocaine on 1p-evoked release for these datasets.
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FIGURE 2 | DAT availability is promoted by α-synuclein. (A) Representative images of PLA puncta (DAT: syn-PLA, red) and DAPI (blue) in dorsal striatum of
Snca-null and SNCA-OVX mice. Scale bar, 25 µm. (B) Quantification of density of DAT: α-synuclein PLA puncta. Unpaired t-test with Welch’s correction for unequal
variances, t(8.156) = 6.285, n = 9 samples, N = 3 animals, ****P < 0.0001. (C) Example Western blots from striatal homogenates showing glycosylated DAT band
( 70 kDa), and actin band ( 42 kDa). (D) DAT levels (relative to actin) in Snca-wt, Snca-null, SNCA-OVX and DAT-Cre+/+ mice. One-way ANOVA: F(3,16) = 1.03,
P = 0.001. Post hoc Dunnett’s multiple comparisons test, C57BL/6J vs. DAT-Cre+/+, **P < 0.01. (E) Representative images of DAT immunofluorescence (IF) in
dorsal striatum. Scale bar, 25 µm. (F) Quantification of DAT IF. Unpaired t-test, t(34) = 4.29, ∗∗∗P = 0.0001, n = 18, N = 3. (G) Representative autoradiograms
demonstrating the distribution of 3H-cocaine binding sites. (H) Mean ± SEM 3H-cocaine binding sites in striatum. One-way ANOVA: F(3,7) = 2.47, post hoc Dunnett’s
comparisons tests for genotype, N = 3 per genotype, ∗∗∗P < 0.001. (I) Western blot from striatal homogenates showing pan-species α-synuclein band (16 kDa) and
actin band (42 kDa) with normalized quantification of α-synuclein expression, from Snca-wt and SNCA-OVX. N = 2 animals.
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FIGURE 3 | Applied cholesterol potentiates DAT function. (A) Mean [DA]o ± SEM vs. time evoked by single pulses (arrow) in CPu from Snca-null mice incubated in
vehicle or ws-cholesterol. ****P < 0.0001. (B) One-phase exponential decay curve fits for falling phases of mean [DA]o transients concentration-matched. k (s−1)
2.54 (vehicle) vs. 3.14 (cholesterol), half-lives (t(1/2)) are indicated by for vehicle (fine line) and cholesterol (thick dotted), F(1,617) = 46.4, ***P < 0.0001. (C) Mean [DA]o
(normalized to control conditions) ± SEM vs. time evoked by single pulses (arrow) in CPu of Snca -null mice, in control (black) and in the presence of cocaine (blue)
from slices incubated in vehicle or cholesterol. ****P < 0.0001. (D) Summary of effects of cocaine on mean peak [DA]o ± SEM, normalized to pre-cocaine condition.
Two-way ANOVA: effect of cholesterol, F(1,8) = 14.9, ***P = 0.005; effect of genotype, F(1,8) = 15.8, P = 0.004; Genotype x cocaine interaction, F(1,8) = 0.15, P = 0.70.
(E) Secondary ion mass spectrometry (SIMS) analyses of Snca -null (top) and SNCA-OVX (bottom) striatum groups obtained from the striatum region of brain tissue
in positive ion mode. Cholesterol (green arrow) and galactosylceramide (galcer; purple arrow) signal intensity (normalized to the number of selected pixels for the
spectrum). (F) Statistical comparison of striatal lipid species cholesterol and galcer (32:1). In SNCA−/− (unfilled bars) and SCNA-OVX (filled bars) Mean ± SEM
(normalized to the total ion count). 2-sample T-test, n = 12, ∗∗∗P < 0.001.
with α-synuclein (soluble monomeric and oligomeric forms)
being able to potentiate cholesterol efflux, via the ATP-binding
cassette (ABC) transporter ABCA1 (Hsiao et al., 2017).
Elevated cholesterol efflux could reduce cellular cholesterol level,
consistent with the low cellular cholesterol content seen in
SNCA-OVXmeasured by ToF-SIMS, and cholesterol efflux could
promote extracellular cholesterol, consistent with elevated DAT
function seen in SNCA-OVXmice. To test whether elevated DAT
function in SNCA-OVX mice is due to enhanced extracellular
cholesterol we tested whether an inhibitor of ABCA1 activity
(probucol, 5 µM) could decrease the effect of cocaine in
peak [DA]o. After incubation of striatal slices from SNCA-
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FIGURE 4 | Decreasing extracellular cholesterol in SNCA-OVX striatum decreases DAT control of DA release. (A–D) Mean peak [DA]o ± SEM evoked by 1p vs. time
(min) in CPu of SNCA-OVX mice incubated in vehicle control (unfilled circles) or (A) Probucol (black), (D) Nystatin 25 µg/ml (gray), or 100 µg/ml (black). Cocaine
(5 µM) added at 12.5 min (blue bar). Two-way ANOVAs: (A) repeated measures for time, time x probucol interaction, F(17,170) = 10.13, P < 0.0001; effect of
probucol, F(1,10) = 14.19, **P = 0.0037. (D) time x nystatin interaction, F(34,204) = 4.95, P < 0.0001; effect of nystatin, F(2,12) = 5.98, *P = 0.016. (B–E) Mean [DA]o
(normalized to control conditions) ± SEM (shaded) vs. time evoked by single pulses (arrow) in CPu of SNCA-OVX mice from slices incubated in vehicle or (C)
probucol (5 µM) or (E) nystatin 100 µg/ml (thick line) in control condition (black) or with cocaine (blue). (C–F) [DA]o before and after cocaine from slices treated with
vehicle and (C) probucol or (F) nystatin 100 µg/ml. Two-way ANOVA, repeated measures by cocaine treatment: (C) probucol x cocaine interaction, F(1,10) = 6.51,
‡P = 0.029; (F) nystatin x cocaine interaction, F(1,8) = 7.16, ‡P = 0.028. (G) Summary of k (s−1) for averaged falling phase transients in vehicle, probucol, or nystatin.
One-way ANOVA: F(2,18) = 5.17, P = 0.017, Dunnett’s post-tests: vehicle vs. probucol, *P = 0.024; vehicle vs. nystatin, *P = 0.038.
OVX mice in probucol, we found that the effect of cocaine
was less than in vehicle-treated slices (Figures 4A–C). In
addition, we tested whether nystatin (25–100 µg/ml), which
chelates extracellular/sequesters lipid raft cholesterol, could also
decrease the effect of cocaine. Indeed, nystatin, decreased the
effect of cocaine on peak [DA]o in a concentration-dependent
manner (Figures 4D–F), and both nystatin and probucol led
to a significant slowing of the falling phases of DA transients
(Figure 4G). Together these data support the hypothesis that
α-synuclein potentiates DAT function via its ability to potentiate
cholesterol efflux via the ABCA1 transporter, leading to an
elevation in extracellular cholesterol that in turn potentiates
DAT function.
DISCUSSION
Here, we report that striatal DAT function is enhanced in
the SNCA-OVX mouse model of PD, compared to Snca-
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null background controls. Furthermore, we show changes to
cholesterol and other lipid levels, that can directly impact
DAT function. These findings demonstrate that the intersecting
biologies of α-synuclein and cholesterol can powerfully regulate
DAT function.
In SNCA-OVX mice, we found close spatial localization of
α-synuclein and DAT, and increased DAT function in several
aspects relative to Snca-null controls. DAT function in wild-type
mice represented an intermediate level between the extremes
of SNCA-OVX and Snca-null mice. Extracellular DA clearance
kinetics were enhanced, the effects of DAT inhibitors on peak
[DA]o were promoted, and there was enhanced facilitation of
DA release at short IPIs in SNCA-OVX mice. Correspondingly,
we found evidence of elevated membrane DAT levels, from
in situ autoradiography and DAT-immunocytochemistry, but
not greater total DAT expression. We found that both the
Vmax and Km for DA uptake were greater than in Snca-null
control mice. These data therefore indicate that α-synuclein is
promoting DAT availability, and also changing DA binding.
These outcomes could also potentially be driven by an increase
in forward trafficking of DAT to the membrane, a decrease in
reverse trafficking and/or a change in conformation, including
the relative outward- vs. inward-facing DAT. Our findings
that Km appears increased in SNCA-OVX mice in addition to
Vmax, appears to indicate that α-synuclein not only increases
the number of DA-translocation sites, but also affects how
DA binds to DAT. One candidate explanation might be an
underlying change to the stoichiometry of DATs e.g., an increase
in monomeric/oligomeric (dimer or tetramer) ratio, which
was not assessed here but is known to affect the number of
actively translocating DAT units and their availability to bind
substrate (Gur et al., 2017; Zhen and Reith, 2018). Interestingly,
cholesterol has been shown to affect how DA binds to DAT
by promoting an outward facing confirmation (Hong and
Amara, 2010; Jones et al., 2012). Intriguingly, our lipid analyses
identified significantly lower levels of cellular cholesterol in
SNCA-OVX mice, which is consistent with a report that soluble
monomeric α-synuclein promotes cholesterol efflux, via the
ABCA1 transporter (Hsiao et al., 2017). Potentially, the level of
ceramide and cholesterol are related in a way that an increasing
level of ceramide at the cell membrane promotes the release
of cholesterol to the extracellular space, resulting in a lower
level of cholesterol at the cell membrane (Mohammadi et al.,
2018). Cholesterol efflux via ABCA1 transporter can occur
from neurons or astrocytes (Lee et al., 2020). Correspondingly,
we found that probucol, which decreases ABCA1 transporter
function, or a cholesterol chelator, decreased the effect of cocaine
on elevating peak evoked [DA]o. These findings together suggest
that the elevated DAT function in SNCA-OVXmice is dependent
on extracellular cholesterol, reflected in reduced membrane
cholesterol levels. This hypothesis should be explored in future
work and in other PD models.
These findings support a converging biology of α-synuclein,
cholesterol and DAT, but the precise mechanism is still to be
characterized. DATs are subject to extensive post-translation
modifications (phosphorylation, palmitoylation, glycosylation,
ubiquitination), express many regulatory binding domains
(CRAC, SH3) and associate with other molecular regulators
of DA release (D2Rs, RIM, synt-1; Vaughan and Foster,
2013). Both cholesterol and α-synuclein have scope to affect
many of these parameters both directly and indirectly e.g., α-
synuclein and cholesterol affecting VGCC function (Ronzitti
et al., 2014), which in turn interacts with DAT function (Kile
et al., 2010; Cameron et al., 2015). Furthermore, although
DAT expression is restricted to DA axons, cholesterol and
α-synuclein are more ubiquitous. Therefore, our observed
effects of α-synuclein induced cholesterol efflux might involve
other interacting striatal cellular networks, neuronal and
non-neuronal.
The overall up-regulation of DAT function in SNCA-OVX
mice also offers insights into another previous observation in
this mouse model. DATs can apparently limit the recruitment
of vesicles for release (Venton et al., 2006; Kile et al., 2010),
and we have previously shown that vesicles within DA axons
in SNCA-OVX mice are less dispersed and more tightly
clustered, and that DA releasability is restricted (Janezic et al.,
2013). Elevated DAT function could be a mechanism that
contributes to this redistribution of DA vesicles and limited
DA release.
We note that the increases to DAT function in SNCA-
OVX mice, compared to background control mice, also
similar parallel effects of knocking down a different protein
in DA neurons, the Ca2+ binding protein calbindin-D28k
(calb1; Brimblecombe et al., 2019). Calb1 expression in
midbrain DA neurons is negatively correlated with vulnerability
to degeneration in PD, being lower in SN neurons that
are more vulnerable. A multiple hit hypothesis has been
suggested for driving DA neuron degeneration in PD, arising
from hits that include α-synuclein burden, Ca2+ burden
and oxidative stress due to DA load after uptake (Sulzer,
2007; Mosharov et al., 2009; Post et al., 2018; Surmeier,
2018). We speculate that the enhanced DA uptake rates
caused by α-synuclein could have important implications
for pathology in Parkinson’s. For example, increased DA
uptake would decrease the extracellular availability of DA for
acting on post-synaptic targets, exacerbating the effects of a
deficit in DA release. Furthermore, elevated DAT function
might increase intracellular levels of DA and provide an
additional source of oxidative stress due to production of
toxic metabolites, especially if coupled with low VMAT levels
(Miller et al., 1999; Masoud et al., 2015). Our findings that
both cholesterol and α-synuclein function are linked to DA
uptake biology, indicate that the pathological gain of each
individual hit will not act independently, but co-operatively
through biological interactions.
In conclusion, we show that human α-synuclein promotes
multiple facets of the ways in which DATs regulate DA
release and extracellular levels, through mechanisms that
depend on extracellular cholesterol. The interacting biology
of α-synuclein, cholesterol and DATs leads to changes to
DAT function and DA signaling in this mouse model of
PD that will diminish DA output, and could potentiate the
burden of cytosolic DA, potentially promoting vulnerability
to degeneration.
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